(Q41503593)

1 October 2017

title

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer (English)

1 reference

1 October 2017

0 references

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Khanh Do

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giovanna Speranza

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rachel Bishop

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sonny Khin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Larry Rubinstein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Robert J Kinders

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Michelle Eugeni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Michael H Lam

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

L Austin Doyle

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

James H Doroshow

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Shivaani Kummar

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 February 2015

1 reference

Investigational New Drugs

1 October 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

720-728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637165%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-015-0212-z

1 June 2020

exact match

0 references

cites work

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

The statistics of phase 0 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0212-Z

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25637165

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25637165